Compare Sana Biotechnology Inc (SANA) vs Uber Technologies Inc (UBER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Uber Technologies Inc — how do they compare? Sana Biotechnology Inc trades at $3.24 (market cap $1.03B), while Uber Technologies Inc trades at $71.62 (market cap $149.37B). The key difference: Uber Technologies Inc is far larger — about 145× Sana Biotechnology Inc's market cap. Which is the better fit depends on your goals.
| SANA | UBER | |
|---|---|---|
Market Cap | $1.03B | $149.37B |
Sector | Health | Industrials |
52-Week High | $5.92 | $100.10 |
52-Week Low | $2.68 | $65.94 |
Enterprise Value | $946.04M | $158.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Uber's stock trades at $71.08, down 6.18% today, amid a bearish technical signal but strong fundamentals. Revenue grew to $52.02B in 2025 with a net income of $10.05B, though Q4 2025 earnings missed expectations. Recent news highlights strategic shifts toward autonomous vehicles, including robotaxi pilots in Spain and Germany, alongside cost-cutting measures like HR layoffs and AI spending caps.
The outlook is mixed: robust revenue growth and a dominant market position support upside, but competitive pressures, regulatory risks, and a projected negative cash flow in 2026 pose challenges. Analyst consensus is strongly bullish with a $102.56 price target, suggesting significant potential if execution aligns with autonomous vehicle initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →
